Your Reliable Partner in Pharmaceutical Contract Manufacturing
Vanelloid Pvt. Ltd. was founded in June 2020 with a vision to support small and medium-sized marketing companies looking to establish their brands in the highly competitive pharmaceutical industry. As a leading contract pharmaceutical manufacturing company based in Ludhiana, Punjab, we specialize in Non-Beta Lactam Tablets and Non-Beta Lactam Capsules, offering pharmaceutical contract manufacturing services that meet international quality standards, including WHO-GMP guidelines and ISO:9000 and ISO:14000 certifications.
Our state-of-the-art facility is designed to handle the evolving needs of the pharma industry, with a focus on quality, timely delivery, and innovation. Our expertise spans various therapeutic areas, including de-addiction formulations, CNS (Neuro-Psychiatry), diabetic care, and cardiac care. With a rapidly growing presence across North India, we currently serve 94 clients, including prominent de-addiction centers in 64 cities across four states.
At Vanelloid Pvt. Ltd., we focus on several therapeutic areas where our manufacturing expertise makes a significant impact. These include:
Our manufacturing facility adheres to the highest global standards, ensuring that we deliver stable, safe, and effective pharmaceutical products. Key highlights include:
Since our inception in 2020, Vanelloid has rapidly expanded its operations, establishing a solid reputation as one of the most trusted pharmaceutical contract manufacturing organizations in North India. With a current client base of 94 clients and a growing footprint across 64 cities, we continue to deliver value through innovation and high standards of quality.
Looking ahead, Vanelloid is set to expand its capabilities and market presence. By 2026, we aim to support 500 De-addiction Centers across India, providing them with the high-quality, stable formulations they need to help patients on their recovery journey. Our continued focus on research and development will also enable us to expand into new therapeutic segments and strengthen our position as a leader in contract development and manufacturing organization (CDMO) services.